Brief: Medincell Completes Phase 3 Trial For Olanzapine LAI In Schizophrenia

Medincell SA

10/02/2025 07:05

Feb 10 (Reuters) - Medincell SA  MEDCL.PA :
    * COMPLETION OF THE PIVOTAL PHASE 3 TRIAL FOR OLANZAPINE LAI
IN
SCHIZOPHRENIA CONDUCTED BY TEVA PHARMACEUTICALS
    * TO RECEIVE A $5 MILLION DEVELOPMENT MILESTONE PAYMENT FROM
TEVA
WITH SOLARIS STUDY COMPLETION
    * TEVA PREPARING FOR NDA SUBMISSION IN H2 2025

Source text:  ID:nBw89DlHta 
Further company coverage:  MEDCL.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))